Matrix metalloproteinase-12 cleaved fragment of titin as a predictor offunctional capacity in patients with heart failure and preserved ejection fraction
Impact
Scholar |
Other documents of the author: Palau, Patricia; Reese-Petersen, Alexander; Domínguez Mafé, Eloy; Ramón, José María; López, Laura; Mollar, Anna; Chorro, Francisco J.; Sanchis, Juan; Núñez, Julio
Metadata
Show full item recordcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONThis resource is restricted
https://doi.org/10.1080/14017431.2020.1831052 |
Metadata
Title
Matrix metalloproteinase-12 cleaved fragment of titin as a predictor offunctional capacity in patients with heart failure and preserved ejection fractionAuthor (s)
Date
2020Publisher
Taylor and FrancisISSN
1401-7431; 1651-2006Bibliographic citation
PALAU, Patricia, et al. Matrix metalloproteinase-12 cleaved fragment of titin as a predictor of functional capacity in patients with heart failure and preserved ejection fraction. Scandinavian Cardiovascular Journal, 2020, p. 1-6Type
info:eu-repo/semantics/articlePublisher version
https://www.tandfonline.com/doi/full/10.1080/14017431.2020.1831052Version
info:eu-repo/semantics/publishedVersionAbstract
Objectives.Serum levels of matrix metalloproteinase-12 cleaved fragment of titin (TIM), a novel circula-tory biomarker specific for cardiac titin degradation, has emerged as a potential biomarker in cardio-vascular ... [+]
Objectives.Serum levels of matrix metalloproteinase-12 cleaved fragment of titin (TIM), a novel circula-tory biomarker specific for cardiac titin degradation, has emerged as a potential biomarker in cardio-vascular diseases. In this work, we aimed to evaluate the association between TIM and maximalfunctional capacity assessed by the percentage of predicted peak exercise oxygen uptake (pp-peakVO2) in patients with heart failure and preserved ejection fraction (HFpEF).Design.In this post-hoc study, we included 46 stable symptomatic (New York Heart Association II-III) HFpEF patientsenrolled in the TRAINING-HF study (NCT02638961). pp-peak-VO2 was calculated from baseline values.Baseline circulating levels of TIM were measured by competitive ELISA in serum from the TRAINING-HFpatients. The independent association between TIM and pp-peakVO2 was evaluated by multivariatelinear regression analysis.Results.The mean age of the sample was 73.8 ±8.7 years, 56.5% werefemales, and 76.1% were on NYHA II. The medians of pp-peakVO2 and TIM were 60.9% (50.4–69.3),and 130.1 ng/mL (98.1–159.5), respectively. The median of NT-proBNP was 912pg/mL (302–1826). pp-peakVO2 was significant and inversely correlated with TIM (r¼ 41,p¼.005). In multivariate analysis,after adjusting for NYHA class, hypertension, body mass index, and glomerular filtration rate, higherTIM was significantly associated with lower pp-peak VO2 (p¼.029).Conclusions.In this sample of sta-ble and symptomatic HFpEF patients, higher serum levels of TIM identified patients with worse func-tional status. [-]
Is part of
Scandinavian Cardiovascular Journal, 2020, p. 1-6Funder Name
Ministerio de Economía y Competitividad de España a través del Instituto de Salud Carlos III | CIBER-CV
Project code
FIS 17/01736 | 16/11/00420 | FIS 17/00899 | FIS 15/00837 | FEDER
Rights
© 2020 Informa UK Limited, trading as Taylor & Francis Group
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
This item appears in the folowing collection(s)
- MED_Articles [667]